Nucleic Acid Therapeutics Contract Manufacturing Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The nucleic acid therapeutics contract manufacturing market covers outsourced development and production of RNA- and DNA-based pharmaceutical products, including oligonucleotide synthesis, lipid nanoparticle formulation, fill-finish operations, and comprehensive analytical testing services. Valued at approximately $227.3 billion in 2026 with a compound annual growth rate of 8.3%, the market recorded a meaningful increase over the prior year, reflecting sustained momentum across clinical and commercial-stage programs.

• •Encompasses oligonucleotide synthesis, lipid nanoparticle formulation, plasmid DNA production, and fill-finish operations
• •Includes services for siRNA, mRNA, antisense oligonucleotides, aptamers, and gene-editing payloads
• •Year-over-year growth reflects accumulated demand from both advancing clinical pipelines and newly commercialized products

The accelerating pipeline of nucleic acid therapeutics across cardiovascular disease, rare genetic disorders, oncology, and infectious disease indications sustains strong capacity investment from contract manufacturing organizations. The successful deployment of mRNA vaccines established scalable manufacturing infrastructure, regulatory frameworks, and public-health supply chains that the industry is now adapting for broader therapeutic applications beyond infectious disease.

• •Expanding clinical-stage pipeline of siRNA, ASO, and mRNA therapeutics across multiple therapeutic areas
• •Vaccine-era manufacturing infrastructure being repurposed and expanded for therapeutic mRNA and other modalities
• •Regulatory pathways maturing for oligonucleotide drugs, reducing approval timelines and encouraging contract outsourcing

The market is segmented by product type into oligonucleotides, mRNA therapeutics and vaccines, and plasmid DNA and gene-editing constructs, each requiring distinct manufacturing platforms and quality frameworks. Geographically, North America holds the largest share, followed by Europe and the Asia-Pacific region, where growing domestic biopharmaceutical industries and government-supported biotechnology initiatives are driving regional manufacturing demand.

• •Oligonucleotide synthesis and mRNA lipid nanoparticle formulation represent the largest service categories by revenue
• •North America leads in market share, supported by FDA-approved RNA drugs and a robust venture-funded biotechnology sector
• •Asia-Pacific is the fastest-growing regional market, driven by capacity expansion in established pharmaceutical manufacturing hubs

Who are the notable companies in the industry?

The market exhibits a moderately fragmented competitive structure, with a mix of large integrated contract development and manufacturing organizations providing end-to-end services alongside smaller specialty producers focused on specific nucleic acid modalities or individual process steps. Capacity concentration is heavily weighted toward established biopharmaceutical manufacturing regions, though emerging geographic hubs are investing in oligonucleotide-specific facilities to capture growing regional demand.

• •Combination of large integrated CDMOs offering full-service platforms and smaller specialty CMOs with oligonucleotide-specific expertise
• •Core process routes include solid-phase oligonucleotide synthesis, in vitro transcription for mRNA production, and bacterial fermentation for plasmid DNA
• •Regional manufacturing capacity concentrated in North America, Western Europe, and key Asia-Pacific pharmaceutical manufacturing centers

What are the recent trends and outlook?

Advances in delivery technologies, particularly lipid nanoparticles and GalNAc conjugate systems, are expanding the addressable therapeutic population and creating new manufacturing complexity that drives sustained contract manufacturing demand. The market is expected to maintain its 8.3% annual growth trajectory through the forecast period, supported by continued commercialization of RNA drugs, pipeline diversification across indications, and increasing adoption of AI-driven oligonucleotide design tools.

• •Lipid nanoparticle and conjugate delivery system manufacturing is becoming a core differentiated capability for contract manufacturers
• •Pipeline of nucleic acid therapeutics continues to expand, with increasing numbers of products advancing through Phase III trials toward commercialization
• •Investment in modular and flexible manufacturing capacity to accommodate diverse nucleic acid modalities and variable batch sizes